Kikwit Ebola Virus Disease Progression in the Rhesus Monkey Animal Model

Viruses

Jing Qin¹  Ian Crozier²  Rebecca Shim³  James Logue³  TimothyK. Cooper³  PeterB. Jahrling³  RichardS. Bennett³  LisaE. Hensley³  TraceyL. Burdette³  Russell Byrum³  Danny Ragland³  DavidX. Liu³  M.Colin Waters³  KrisztinaB. Janosko³  RebeccaJ. Reeder³  Marisa St. Claire³  TylerM. Brady³  Ricky Adams³  DonnaL. Perry³  Kyra Hadley³  William Dowling⁴ 

[1] Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, USA;Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD 21702 USA;Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, MD 27102, USA;Research Resources Section, Office of Biodefense, Research Resources, and Translational Research/Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892-9825, USA;

关键词: Ebola virus;    Kikwit;    FANG;    rhesus monkey;    natural history;    emerging pathogens;   

DOI  :  10.3390/v12070753

来源: DOAJ

【 摘 要 】

Ongoing Ebola virus disease outbreaks in the Democratic Republic of the Congo follow the largest recorded outbreak in Western Africa (2013–2016). To combat outbreaks, testing of medical countermeasures (therapeutics or vaccines) requires a well-defined, reproducible, animal model. Here we present Ebola virus disease kinetics in 24 Chinese-origin rhesus monkeys exposed intramuscularly to a highly characterized, commercially available Kikwit Ebola virus Filovirus Animal Non-Clinical Group (FANG) stock. Until reaching predetermined clinical disease endpoint criteria, six animals underwent anesthesia for repeated clinical sampling and were compared to six that did not. Groups of three animals were euthanized and necropsied on days 3, 4, 5, and 6 post-exposure, respectively. In addition, three uninfected animals served as controls. Here, we present detailed characterization of clinical and laboratory disease kinetics and complete blood counts, serum chemistries, Ebola virus titers, and disease kinetics for future medical countermeasure (MCM) study design and control data. We measured no statistical difference in hematology, chemistry values, or time to clinical endpoint in animals that were anesthetized for clinical sampling during the acute disease compared to those that were not.

【 授权许可】

Unknown